angiotensin ii type 1 receptor blockers

Summary

Summary: Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.

Top Publications

  1. ncbi Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
    Hermann Haller
    Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
    N Engl J Med 364:907-17. 2011
  2. pmc Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
    Ilke Sipahi
    Harrington McLaughlin Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    Lancet Oncol 11:627-36. 2010
  3. pmc Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism
    Jennifer P Habashi
    Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Science 332:361-5. 2011
  4. ncbi Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
    Stephen C Benson
    Department of Biological Sciences, California State University, Hayward, USA
    Hypertension 43:993-1002. 2004
  5. ncbi Irbesartan in patients with heart failure and preserved ejection fraction
    Barry M Massie
    University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco 94121, USA
    N Engl J Med 359:2456-67. 2008
  6. ncbi Feasibility of treating prehypertension with an angiotensin-receptor blocker
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
    N Engl J Med 354:1685-97. 2006
  7. ncbi Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL
    Dick de Zeeuw
    Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands
    Kidney Int 65:2309-20. 2004
  8. ncbi Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis
    Ken ichiro Okada
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Circulation 110:705-12. 2004
  9. ncbi The podocyte's response to injury: role in proteinuria and glomerulosclerosis
    S J Shankland
    Department of Medicine, Division of Nephrology, University of Washington, Seattle, Washington 98195, USA
    Kidney Int 69:2131-47. 2006
  10. ncbi Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity
    Michael Schupp
    Center for Cardiovascular Research, Institut fur Pharmakologie und Toxikologie, Campus Charite Mitte, Charite Universitatsmedizin Berlin, Berlin, Germany
    Circulation 109:2054-7. 2004

Research Grants

  1. Angiotensin II Mediates Early Changes in Diabetic Kidney
    Helmy Siragy; Fiscal Year: 2007
  2. AT2 Receptor Modulates Renal Angiotensin II Levels
    Helmy Siragy; Fiscal Year: 2005
  3. Oxidative Stress and Genetics of Prehypertension
    Shawna Nesbitt; Fiscal Year: 2004
  4. MODERATE ALCOHOL USE--CARDIOVASCULAR RISKS AND BENEFITS
    Thomas Giles; Fiscal Year: 2001
  5. ATHEROGENESIS AND THE BONE MARROW ANGIOTENSIN SYSTEM
    Carlos Ferrario; Fiscal Year: 2004
  6. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2003
  7. WHY DO METABOLIC RISK FACTORS CLUSTER WITH HYPERTENSION?
    Theodore Kurtz; Fiscal Year: 2003
  8. AASK Cohort Study
    George Bakris; Fiscal Year: 2007
  9. ANG II AND IGF-1 INTERACTION IN CARDIOVASCULAR TISSUE
    James Sowers; Fiscal Year: 2003
  10. Estrogen Modulates Injury-Induced Inflammation
    Suzanne Oparil; Fiscal Year: 2007

Detail Information

Publications322 found, 100 shown here

  1. ncbi Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
    Hermann Haller
    Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
    N Engl J Med 364:907-17. 2011
    ..We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria...
  2. pmc Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
    Ilke Sipahi
    Harrington McLaughlin Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    Lancet Oncol 11:627-36. 2010
    ..We assessed whether ARBs affect cancer occurrence with a meta-analysis of randomised controlled trials of these drugs...
  3. pmc Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism
    Jennifer P Habashi
    Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Science 332:361-5. 2011
    ..These data highlight the protective nature of AT2 signaling and potentially inform the choice of therapies in MFS and related disorders...
  4. ncbi Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
    Stephen C Benson
    Department of Biological Sciences, California State University, Hayward, USA
    Hypertension 43:993-1002. 2004
    ....
  5. ncbi Irbesartan in patients with heart failure and preserved ejection fraction
    Barry M Massie
    University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco 94121, USA
    N Engl J Med 359:2456-67. 2008
    ..Therefore, we studied the effects of irbesartan in patients with this syndrome...
  6. ncbi Feasibility of treating prehypertension with an angiotensin-receptor blocker
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
    N Engl J Med 354:1685-97. 2006
    ..Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension...
  7. ncbi Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL
    Dick de Zeeuw
    Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands
    Kidney Int 65:2309-20. 2004
    ....
  8. ncbi Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis
    Ken ichiro Okada
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Circulation 110:705-12. 2004
    ..The ER responds to stress by upregulating ER chaperones, but prolonged and/or excess ER stress leads to apoptosis. However, the potential role of ER stress in pathophysiological hearts remains unclear...
  9. ncbi The podocyte's response to injury: role in proteinuria and glomerulosclerosis
    S J Shankland
    Department of Medicine, Division of Nephrology, University of Washington, Seattle, Washington 98195, USA
    Kidney Int 69:2131-47. 2006
    ..It is the hope that by delineating the events following injury to podocytes, therapies might be developed to reduce the burden of proteinuric renal diseases...
  10. ncbi Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity
    Michael Schupp
    Center for Cardiovascular Research, Institut fur Pharmakologie und Toxikologie, Campus Charite Mitte, Charite Universitatsmedizin Berlin, Berlin, Germany
    Circulation 109:2054-7. 2004
    ..The peroxisome proliferator-activated receptor-gamma (PPARgamma) is the central regulator of insulin and glucose metabolism improving insulin sensitivity. We investigated the regulation of PPARgamma function by ARBs...
  11. ncbi Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients
    Yoshio Matsui
    Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, 3311 1 Yakushiji, Shimotsuke, Tochigi, Japan
    Hypertension 54:716-23. 2009
    ..0 mg) and hydrochlorothiazide (12.5 mg), despite the lack of a significant difference in brachial systolic BP reduction between the 2 treatments...
  12. ncbi Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
    Marvin A Konstam
    Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA
    Lancet 374:1840-8. 2009
    ..We compared the effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure...
  13. ncbi Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 119:530-7. 2009
    ..We compared the effect of aliskiren, the first orally active direct renin inhibitor, the angiotensin-receptor blocker losartan, and their combination on the reduction of LV mass in hypertensive patients...
  14. pmc Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study
    Ikuo Saito
    Keio University Health Center, Kanagawa, Japan
    Hypertens Res 36:177-82. 2013
    ..The HONEST Study is expected to provide evidence showing the relationship between baseline and on-treatment CBP and HBP levels (both first and second measurements) and CV events...
  15. pmc Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study
    E Imai
    Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa Ku, Nagoya, Aichi 466 8550, Japan
    Diabetologia 54:2978-86. 2011
    ..The renal and cardiovascular protective effects of angiotensin receptor blocker (ARB) remain controversial in type 2 diabetic patients treated with a contemporary regimen including an angiotensin converting enzyme inhibitor (ACEI)...
  16. pmc Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome
    Jennifer P Habashi
    Howard Hughes Medical Institute and Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Science 312:117-21. 2006
    ....
  17. ncbi Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
    Dick de Zeeuw
    Department of Clinical Pharmacology, Groningen University Medical Center, Ant Deusinglaan 1, 9713 AV Groningen, Netherlands
    Circulation 110:921-7. 2004
    ..Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention...
  18. ncbi Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study
    Srikanth Sola
    Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30303, USA
    Circulation 111:343-8. 2005
    ..We evaluated the ability of irbesartan, an angiotensin receptor blocker, and lipoic acid, an antioxidant, to affect endothelial function and inflammation in patients with the metabolic syndrome...
  19. ncbi Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease
    Regina Kunz
    Basel Institute for Clinical Epidemiology and Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland
    Ann Intern Med 148:30-48. 2008
    ..Reports suggest that angiotensin-receptor blockers (ARBs) reduce proteinuria, but results are variable. The relative effect of ARBs and angiotensin-converting enzyme (ACE) inhibitors, and their combined administration, remains uncertain...
  20. ncbi Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension
    David B Matchar
    Duke Center for Clinical Health Policy Research, Duke Clinical Research Institute, Duke University, and Durham U S Department of Veterans Affairs Medical Center, Durham, North Carolina 27705, USA
    Ann Intern Med 148:16-29. 2008
    ..The relative effectiveness of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) for lowering blood pressure is unknown...
  21. ncbi Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
    ..We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes...
  22. ncbi Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension
    William B White
    Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030 3940, USA
    Hypertension 57:413-20. 2011
    ..Azilsartan medoxomil could provide higher rates of hypertension control within the ARB class...
  23. ncbi Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer
    Takeo Kosaka
    Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Prostate 67:41-9. 2007
    ..This study was then undertaken to investigate the effects of AT1R blockade using candesartan in prostate cancer (PCa)...
  24. ncbi Telmisartan: a different angiotensin II receptor blocker protecting a different population?
    M Burnier
    Division of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Int Med Res 37:1662-79. 2009
    ..A class effect for ARBs cannot be assumed. To date, telmisartan is the only ARB that has been shown to reduce cardiovascular risk in at-risk cardiovascular patients...
  25. ncbi Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation
    Danilo Fliser
    Division of Nephrology, Department of Internal Medicine, Medical School Hannover, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    Circulation 110:1103-7. 2004
    ....
  26. ncbi Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy
    Giovanni Corrao
    Department of Statistics, Unit of Biostatistics and Epidemiology, University of Milano Bicocca, Milan, Italy
    J Hypertens 26:819-24. 2008
    ..To assess rates and determinants of treatment discontinuation of or changes in initial antihypertensive drug therapy in a large cohort of patients from Lombardia (Italy)...
  27. pmc A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects
    Masahiro Fujino
    Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
    Hypertens Res 33:1044-52. 2010
    ..In conclusion, irbesartan induced greater beneficial effects than losartan due to small differences between their molecular structures, and these differential effects were both dependent on and independent of the AT₁ receptor...
  28. ncbi Combination therapy in hypertension
    Alan H Gradman
    The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania and Temple University School of Medicine, Philadelphia, PA 15224, USA
    J Am Soc Hypertens 4:42-50. 2010
    ..The advantages and disadvantages of single pill (fixed) drug combinations, and the implications of recent clinical trials involving specific combination strategies will also be discussed...
  29. ncbi A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding
    Juan M Saavedra
    Section on Pharmacology, National Institute of Mental Health, National Institutes of Health, DHHS, Bethesda, MD 20892, USA
    Neuropsychopharmacology 31:1123-34. 2006
    ..We propose that AT1 receptor antagonists can be considered as compounds with possible therapeutic anti-stress and anti-anxiety properties...
  30. ncbi A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists
    Martin C Michel
    Department of Clinical Development and Medical Affairs, Boehringer Ingelheim, 55216 Ingelheim, Germany
    Pharmacol Rev 65:809-48. 2013
    ..Although there is general consensus that a continuous receptor blockade over a 24-hour period is desirable, the clinical relevance of other pharmacological differences between individual ARBs remains to be assessed...
  31. ncbi Reduction of proteinuria with angiotensin receptor blockers
    Jan Galle
    Department of Nephrology and Dialysis at Klinikum Lüdenscheid, Ludenscheid, Germany
    Nat Clin Pract Cardiovasc Med 5:S36-43. 2008
    ..These data support the proposition that blockade of the renin-angiotensin system beyond that required for maximum blood pressure reduction provides optimum renal protection...
  32. ncbi Telmisartan is a potent target for prevention and treatment in human prostate cancer
    Kiyoaki Funao
    Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545 8585, Japan
    Oncol Rep 20:295-300. 2008
    ..Telmisartan may mediate potent antiproliferative effects against PC cells through PPAR-gamma. Thus, Telmisartan is a potent target for prevention and treatment in PC...
  33. ncbi Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation
    Koichi Yamamoto
    Department of Geriatric Medicine, Osaka University Graduate School of Medicine, 2 2 Yamada oka, Suita, Osaka 565 0871, Japan
    Hypertension 54:1353-9. 2009
    ..It might be postulated that inhibition of AKT activation is a mechanism mediating the antiproliferative effects of telmisartan, including in cells lacking AT1 receptors or PPARgamma...
  34. ncbi Multiple templates-based homology modeling enhances structure quality of AT1 receptor: validation by molecular dynamics and antagonist docking
    Pandian Sokkar
    School of Chemistry, Madurai Kamaraj University, Madurai 625021, Tamil Nadu, India
    J Mol Model 17:1565-77. 2011
    ....
  35. ncbi High ambient glucose induces angiotensin-independent AT-1 receptor activation, leading to increases in proliferation and extracellular matrix accumulation in MES-13 mesangial cells
    Naohiro Yano
    Department of Pediatrics, Women and Infants Hospital, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
    Biochem J 423:129-43. 2009
    ..These results suggest that high ambient glucose induces activation of AT-1R in an Ang II-independent manner to transactivate PI3K, resulting in proliferation and ECM accumulation in mesangial cells...
  36. ncbi The importance of home blood pressure measurement for preventing stroke and cardiovascular disease in hypertensive patients: a sub-analysis of the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospectiv
    Kazuyuki Shimada
    Jichi Medical University School of Medicine, Shimotsuke, Japan
    Hypertens Res 31:1903-11. 2008
    ..However, further investigation is required to fully characterize the cardiovascular risks associated with masked HT among Japanese patients receiving treatment...
  37. ncbi Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial
    Atsushi Hirohata
    Sakakibara Heart Institute of Okayama, Okayama, Japan
    J Am Coll Cardiol 55:976-82. 2010
    ..The aim of this study was to evaluate the impact of olmesartan on progression of coronary atherosclerosis...
  38. ncbi High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes
    Vivek P Singh
    Division of Molecular Cardiology, Cardiovascular Research Institute, Texas A and M Health Science Center, College of Medicine, Temple, TX 76504, USA
    Am J Physiol Heart Circ Physiol 293:H939-48. 2007
    ..Significantly, NRVM synthesized and retained ANG II intracellularly, which redistributed to the nucleus under high-glucose conditions, suggesting a role for an intracrine mechanism in diabetic conditions...
  39. ncbi Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase
    Chi Yung Yuen
    Institute of Vascular Medicine, Li Ka Shing Institute of Health Sciences, School of Biomedical Sciences, Chinese University of Hong Kong, Shatin, N T, Hong Kong, China
    Cardiovasc Res 90:122-9. 2011
    ....
  40. ncbi I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prosp
    Guillaume Bobrie
    Department of Hypertension, Hopital Europeen Georges Pompidou, Paris, France
    Clin Ther 34:1705-19. 2012
    ..Newer antihypertensive treatment combinations include fixed-dose combinations of an angiotensin receptor blocker and a calcium channel blocker...
  41. ncbi Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production
    Vivek P Singh
    Cardiovascular Research Institute, Texas A and M HSC, Temple, TX 76504, USA
    Am J Physiol Heart Circ Physiol 294:H1675-84. 2008
    ....
  42. ncbi Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial
    Dingliang L Zhu
    Shanghai Ruijin Hospital, Shanghai Institute of Hypertension, 197 Ruijin 2nd Road, Shanghai, China
    Clin Ther 34:1613-24. 2012
    ..Patients with grade 2 or 3 hypertension may require high-dose combination therapy to achieve blood pressure (BP) targets in a timely manner...
  43. ncbi Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial
    Marcello Disertori
    Department of Cardiology, Santa Chiara Hospital, Trento, Italy
    Am Heart J 162:382-9. 2011
    ..In a consistent percentage of cases, AF recurrences are asymptomatic, thus making its clinical management difficult in relation to both therapeutic efficacy and thromboembolic risk...
  44. ncbi Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial
    Toshio Ogihara
    Osaka University Graduate School of Medicine, Osaka, Japan
    Hypertension 51:393-8. 2008
    ..We disclosed that candesartan-based and amlodipine-based regimens produced no statistical differences in terms of the primary cardiovascular end point, whereas candesartan prevented new-onset diabetes more effectively than amlodipine...
  45. ncbi Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive rats
    Toru Dejima
    Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, 3 9 Fukuura, Kanazawa Ku, Yokohama 236 0004, Japan
    J Hypertens 29:1919-29. 2011
    ..In this study we examined whether the regulation of renal ATRAP expression is related to the development of salt-induced hypertension and renal injury as well as to the beneficial effects of AT1R blockade...
  46. pmc Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes
    Tao Pang
    Section on Pharmacology, Division of Intramural Research Programs, Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Hypertens 30:87-96. 2012
    ....
  47. pmc Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation
    Shanna A Arnold
    Division of Surgical Oncology, Department of Surgery and Pharmacology, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
    PLoS ONE 7:e31384. 2012
    ....
  48. ncbi Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study
    Joel M Neutel
    Orange County Research Center, Tustin, CA 92780, USA
    J Clin Hypertens (Greenwich) 14:206-15. 2012
    ..T/A SPCs were well tolerated...
  49. ncbi Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study
    Liyuan Ma
    Department of Evidence Based Medicine, Cardiovascular Institute, Beijing, China
    Am J Cardiovasc Drugs 12:137-42. 2012
    ....
  50. ncbi The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses
    Peter Trenkwalder
    Department of Internal Medicine, Starnberg Hospital, Ludwig Maximilian University Munich, Starnberg, Germany
    J Hypertens Suppl 24:S107-14. 2006
    ..Results in other subgroups were generally consistent with those in the entire SCOPE study population. In patients with slightly low cognitive function at baseline, the MMSE score declined less in the candesartan group...
  51. pmc Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats
    Akira Nishiyama
    Department of Pharmacology, Kagawa University Medical School, 1750 1 Ikenobe, Miki cho, Kita gun, Kagawa 761 0793, Japan
    J Pharmacol Exp Ther 332:1072-80. 2010
    Treatment with angiotensin II type 1 receptor blockers (ARBs) is the first-line therapy for hypertensive patients with diabetic nephropathy...
  52. ncbi A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide
    Matthew R Weir
    University of Maryland School of Medicine, Baltimore, MD, USA
    J Clin Hypertens (Greenwich) 13:404-12. 2011
    ....
  53. ncbi Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES)
    Joachim Schrader
    Department of Internal Medicine, St Josefs Hospital, Cloppenburg, Germany
    Stroke 36:1218-26. 2005
    ..In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality...
  54. pmc Effect of Renin-Angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance
    Stefan Pscherer
    Department of Nephrology and Diabetology, KlinikumTraunstein, Traunstein, Germany
    Diabetes Care 33:914-9. 2010
    ..The study investigated the effect of angiotensin receptor blockers (ARB) on glucose homeostasis and inflammatory parameters in patients with impaired glucose tolerance (IGT)...
  55. ncbi Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy
    Susumu Ogawa
    Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University School of Medicine, Sendai, Japan
    Hypertens Res 30:325-34. 2007
    ..Even among patients treated with an ACEI and/or ARB, lowering BP is important...
  56. ncbi Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis
    Nadine Nagy
    Institut fur Pharmakologie, Universitatsklinikum Essen, Universitat Duisburg Essen, Hufelandstrasse 55, 45122, Essen, Germany
    Basic Res Cardiol 105:29-38. 2010
    ..Thus, biglycan is a pleiotropic target of telmisartan that might contribute to the anti-atherogenic effects of this AT1-antagonist...
  57. ncbi Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction
    N D Vaziri
    Division of Nephrology and Hypertension, University of California, Irvine, CA, USA
    J Pharmacol Exp Ther 323:85-93. 2007
    ..Thus, the study demonstrated a link between up-regulation of Ang II/AT1r system and oxidative stress, inflammation, hypertension, and progression of renal disease in rats with renal mass reduction...
  58. pmc Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure
    Irving H Zucker
    Dept of Cellular and Integrative Physiology, 985850 Nebraska Medical Center, Omaha, NE 68198 5850, USA
    Am J Physiol Heart Circ Physiol 297:H1557-66. 2009
    ..Finally, exercise training reduces both central oxidative stress and AT(1)R expression in animals with CHF. These data strongly suggest that multiple central and peripheral influences dynamically alter AT(1)R expression in CHF...
  59. ncbi Valsartan: more than a decade of experience
    Henry R Black
    New York University Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, New York 10003, USA
    Drugs 69:2393-414. 2009
    ..The combination of valsartan/HCTZ was better tolerated than HCTZ alone. Valsartan is administered once daily for hypertension; doses are usually taken upon awakening. In patients with HF or MI, valsartan is administered twice daily...
  60. ncbi Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models
    Keiji Kusumoto
    Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, Osaka, Japan
    Eur J Pharmacol 669:84-93. 2011
    ..These results suggest that azilsartan medoxomil is a potent angiotensin II receptor blocker that has an attractive pharmacological profile as an antihypertensive agent...
  61. ncbi Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans
    Lionel Coltamai
    Service of Nephrology and Hypertension Consultation, Department of Medicine, CHUV, Lausanne, Switzerland
    J Hypertens 28:520-6. 2010
    ....
  62. ncbi Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study
    Thomas W Littlejohn
    Piedmont Medical Research Associates, Winston Salem, NC 27103, USA
    Postgrad Med 121:5-14. 2009
    ..An angiotensin receptor blocker (ARB) plus a calcium channel blocker (CCB) seems particularly attractive for these difficult-to-control patients...
  63. ncbi Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease
    Maartje C J Slagman
    Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands
    Curr Opin Nephrol Hypertens 19:140-52. 2010
    ..This review discusses the place of dual RAAS blockade in improving these outcomes...
  64. ncbi Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients
    Toshihiro Hamada
    Department of Cardiovascular Medicine, Faculty of Medicine, Tottori University, Yonago, Japan
    Am J Hypertens 21:1157-62. 2008
    ..However, it is still unknown whether the inhibitory effect of losartan on URAT1 contributes to its uricosuric action in humans...
  65. ncbi Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program
    Akshay S Desai
    Department of Cardiology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1959-66. 2007
    ..We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients...
  66. ncbi Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction
    Zamaneh Kassiri
    Department of Physiology, University of Alberta, Edmonton, Canada
    Circ Heart Fail 2:446-55. 2009
    ..We hypothesized that ACE2 deficiency may compromise the cardiac response to myocardial infarction (MI)...
  67. ncbi Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes
    Kwan Yi Chu
    Department of Physiology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories
    Diabetes 55:367-74. 2006
    ..Whether islet AT1R activation plays a role in the pathogenesis of human type 2 diabetes remains to be determined...
  68. ncbi Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure
    Masayuki Shimano
    Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Heart Rhythm 5:451-9. 2008
    ..There is evidence that pioglitazone improves ventricular remodeling in some experimental models...
  69. ncbi Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial
    Gennaro Cice
    Second University of Naples, Naples, Italy
    J Am Coll Cardiol 56:1701-8. 2010
    ....
  70. ncbi Continuous inhibition of the renin-angiotensin system and protection from hypertensive end-organ damage by brief treatment with angiotensin II type 1 receptor blocker in stroke-prone spontaneously hypertensive rats
    Kumiko Takemori
    Department of Pathology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Life Sci 77:2233-45. 2005
    ..This may be due to the low concentration of plasma angiotensin II by continuous inhibition of RAS even after maturation...
  71. ncbi Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II
    Yunzeng Zou
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, 1 8 1 Inohana, Chuo Ku, Chiba 260 8670, Japan
    Nat Cell Biol 6:499-506. 2004
    ..All of these events are inhibited by the AT1 receptor blocker candesartan. Thus, mechanical stress activates AT1 receptor independently of angiotensin II, and this activation can be inhibited by an inverse agonist of the AT1 receptor...
  72. ncbi In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies
    Mami Ojima
    Pharmacology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, Osaka, Japan
    J Pharmacol Exp Ther 336:801-8. 2011
    ..Its tight receptor binding might be expected to produce potent and long-lasting antihypertensive effects in preclinical and clinical settings...
  73. pmc Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications
    Juan M Saavedra
    Section on Pharmacology, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, 10 Center Drive, Building 10, Room 2D 57, Bethesda, MD 20892, USA
    Psychoneuroendocrinology 36:1-18. 2011
    ..Blockade of AT(1) receptors offers a novel and safe therapeutic approach for the treatment of illnesses of increasing prevalence and socioeconomic impact, such as mood disorders and neurodegenerative diseases of the brain...
  74. ncbi Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis
    Christiane Ruster
    Department of Internal Medicine III, Friedrich Schiller University, Erlanger Allee 101, D 07740 Jena, Germany
    J Am Soc Nephrol 22:1189-99. 2011
    ..A better understanding of the multiple morphogenic effects of Ang II may be necessary to develop better strategies to halt the progression of renal disease...
  75. ncbi Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease
    Marc Dilauro
    Division of Nephrology, Departments of Medicine and Cellular and Molecular Medicine, The Ottawa Hospital, and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
    Am J Physiol Renal Physiol 298:F1523-32. 2010
    ..In contrast, ANG-(1-7) does not affect albuminuria after (5/6) Nx. We propose that endogenous ACE2 is renoprotective in CKD...
  76. pmc Medical management of small abdominal aortic aneurysms
    B Timothy Baxter
    University of Nebraska Medical Center, Omaha, NE, USA
    Circulation 117:1883-9. 2008
    ..Additional studies are needed to clarify the potential role of doxycycline, roxithromycin, and statin therapy in the progression of aneurysmal disease...
  77. ncbi Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system
    Michael L Tuck
    Department of Medicine, VA Medical Center, Sepulveda 111E, Building 200, Room 3430, North Hills, CA 91343, USA
    Curr Hypertens Rep 7:240-3. 2005
    ..The results imply that the ARB agent, telmisartan, could treat both the hemodynamic and metabolic aberrations seen in subjects with the metabolic syndrome, such as insulin resistance, glucose intolerance, and hypertension...
  78. ncbi Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury
    Jun Li
    Center for Cardiovascular Research Institute of Pharmacology and Toxicology, Charite University Medicine Berlin, Germany
    FASEB J 19:617-9. 2005
    ..Our data indicate that cerebral AT2 receptors exert neuroprotective actions in response to ischemia-induced neuronal injury, possibly by supporting neuronal survival and neurite outgrowth in peri-ischemic brain areas...
  79. ncbi The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes
    Effie L Gillespie
    School of Pharmacy, University of Connecticut, Storrs, USA
    Diabetes Care 28:2261-6. 2005
    ..Patients who utilize either an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) may experience a decreased incidence of new-onset type 2 diabetes...
  80. ncbi Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice
    Sven Wassmann
    Klinik fur Innere Medizin III, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Circulation 110:3062-7. 2004
    ..Angiotensin II type 1 (AT1) receptor activation is potentially involved in the multifactorial pathogenesis of atherosclerosis...
  81. pmc Circulating transforming growth factor-beta in Marfan syndrome
    Peter Matt
    602 Mason F Lord Bldg, Center Tower, Johns Hopkins University, Baltimore, MD 21239, USA
    Circulation 120:526-32. 2009
    ..We hypothesized that dysregulation of TGF-beta might be mirrored in circulating TGF-beta concentrations...
  82. ncbi Irbesartan in patients with atrial fibrillation
    Salim Yusuf
    Population Health Research Institute, McMaster University, Hamilton, ON, Canada
    N Engl J Med 364:928-38. 2011
    ..The risk of cardiovascular events among patients with atrial fibrillation is high. We evaluated whether irbesartan, an angiotensin-receptor blocker, would reduce this risk...
  83. ncbi The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition
    Steven A Atlas
    James J Peters VA Medical Center, 130 W Kingsbridge Rd, Bronx, NY 10468, USA
    J Manag Care Pharm 13:9-20. 2007
    ..Dysregulation of the RAAS plays an important role in the pathogenesis of cardiovascular and renal disorders...
  84. pmc Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b
    Trevor G Marshall
    Autoimmunity Research Foundation, Thousand Oaks, California 91360, USA
    Theor Biol Med Model 3:1. 2006
    ....
  85. ncbi Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer
    Takeo Kosaka
    Department of Urology, Keio University School of Medicine, Shinjuku ku, Tokyo, Japan
    Prostate 70:162-9. 2010
    ..However, the downstream transcriptional factors induced by Ang II in prostate cancer cells have not been fully elucidated yet...
  86. pmc Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects
    Shin Ichiro Miura
    Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
    J Renin Angiotensin Aldosterone Syst 12:1-7. 2011
    ..This review focuses on the class effects versus molecular effects of ARBs from bench to bedside...
  87. ncbi Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
    Stevo Julius
    University of Michigan, Ann Arbor, USA
    Lancet 363:2022-31. 2004
    ....
  88. pmc Angiotensin II blockade and aortic-root dilation in Marfan's syndrome
    Benjamin S Brooke
    McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    N Engl J Med 358:2787-95. 2008
    ..We evaluated the clinical response to ARBs in pediatric patients with Marfan's syndrome who had severe aortic-root enlargement...
  89. pmc Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states
    Ronald D Cohn
    McKusick Nathans Institute of Genetic Medicine, Baltimore, Maryland 21205, USA
    Nat Med 13:204-10. 2007
    ..Moreover, we show TGF-beta-induced failure of muscle regeneration and a similar therapeutic response in a dystrophin-deficient mouse model of Duchenne muscular dystrophy...
  90. ncbi Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists
    David V Erbe
    Wyeth Research, Cambridge, MA 02140, USA
    Vascul Pharmacol 45:154-62. 2006
    ....
  91. ncbi PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin
    Ronald Clasen
    Center for Cardiovascular Research, Institut fur Pharmakologie und Toxikologie, Charite Campus Mitte, Charite Universitatsmedizin Berlin, Berlin, Germany
    Hypertension 46:137-43. 2005
    ..ARB-induced adiponectin stimulation is likely to be mediated via PPARgamma activation involving a post-transcriptional mechanism...
  92. ncbi Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities
    Juan M Saavedra
    Section on Pharmacology, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, 10 Center Drive, Room 2D 57, Bethesda, Maryland 20892, USA
    Cell Mol Neurobiol 25:485-512. 2005
    ....
  93. ncbi Angiotensin receptors: a new role in cancer?
    Frederique Deshayes
    Institut Cochin, CNRS UMR8104 INSERM U567, Departement de Biologie Cellulaire, 22 rue Mechain, 75014 Paris, France
    Trends Endocrinol Metab 16:293-9. 2005
    ..An overview of the major intracellular signaling pathways associated with AT1R and AT2R activation in cancer cells, as well as in endothelial and inflammatory cells, is presented here...
  94. ncbi Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats
    Michiya Igase
    Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157, USA
    Am J Physiol Heart Circ Physiol 289:H1013-9. 2005
    ....
  95. ncbi Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker
    Eoin O'Brien
    Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland
    Hypertension 49:276-84. 2007
    ....
  96. ncbi The obese patient with diabetes mellitus: from research targets to treatment options
    Arya M Sharma
    Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
    Am J Med 119:S17-23. 2006
    ..Clinical trials with telmisartan are currently investigating the effects of RAS blockade on insulin sensitivity in humans...
  97. pmc Small molecules with similar structures exhibit agonist, neutral antagonist or inverse agonist activity toward angiotensin II type 1 receptor
    Shin Ichiro Miura
    Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
    PLoS ONE 7:e37974. 2012
    ..In addition, all of the experimental data were obtained with functional receptors in a native membrane environment (in situ)...
  98. ncbi Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: an evaluation using the cardio-ankle vascular index (CAVI)
    G Uehara
    Department of Internal Medicine, Takeda Clinic, Kanagawa, Japan
    J Int Med Res 36:1094-102. 2008
    ..We conclude that candesartan is a potentially useful therapy against arterial stiffness in hypertensive patients with type 2 diabetes mellitus...
  99. ncbi A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome
    Wojciech Kosmala
    Department of Cardiology, Wroclaw Medical University, Wroclaw, Poland
    JACC Cardiovasc Imaging 4:1239-49. 2011
    ....
  100. ncbi Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland
    Andrew J Palmer
    Center for Outcomes Research CORE, Binningen Basel, Switzerland
    Swiss Med Wkly 136:346-52. 2006
    ....
  101. ncbi Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial
    Yan Miao
    Department of Clinical Pharmacology, University Medical Centre Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Hypertension 58:2-7. 2011
    ..These findings support the view that SUA may be a modifiable risk factor for renal disease...

Research Grants65

  1. Angiotensin II Mediates Early Changes in Diabetic Kidney
    Helmy Siragy; Fiscal Year: 2007
    ..The proposed studies will help understand the mechanisms that are involved in diabetic the development of new therapeutic modalities to prevent or slowdown the development ..
  2. AT2 Receptor Modulates Renal Angiotensin II Levels
    Helmy Siragy; Fiscal Year: 2005
    ..Data obtained from this proposal will lead to increased understanding of the pathophysiology of hypertension and development of novel therapies for its management. ..
  3. Oxidative Stress and Genetics of Prehypertension
    Shawna Nesbitt; Fiscal Year: 2004
    ..abstract_text> ..
  4. MODERATE ALCOHOL USE--CARDIOVASCULAR RISKS AND BENEFITS
    Thomas Giles; Fiscal Year: 2001
    ..The exacerbation or prevention of EIH will be related to drug effects on the cell-signaling pathway. This research can define the cell-signaling pathway in EIH and provide new and novel approaches to treating EIH. ..
  5. ATHEROGENESIS AND THE BONE MARROW ANGIOTENSIN SYSTEM
    Carlos Ferrario; Fiscal Year: 2004
    ..The proposed research will uncover novel mechanisms of atherogenesis that may have significant impact in the development of new therapeutic modalities applicable to cardiovascular and blood vessel diseases. ..
  6. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2003
    ..Under this alternative hypothesis, the results of the cDNA microarray analysis will be used to identify potential downstream target genes whose expression is altered by the primary genetic defect on chromosome 1. ..
  7. WHY DO METABOLIC RISK FACTORS CLUSTER WITH HYPERTENSION?
    Theodore Kurtz; Fiscal Year: 2003
    ....
  8. AASK Cohort Study
    George Bakris; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
  9. ANG II AND IGF-1 INTERACTION IN CARDIOVASCULAR TISSUE
    James Sowers; Fiscal Year: 2003
    ..Thus, the proposed investigation will explore the role of PI3-kinase in mediating the cardiovascular interactions of AngII/IGF-1 after both short-term in vitro Ang II exposure and longer-term in vivo Ang II tissue excess. ..
  10. Estrogen Modulates Injury-Induced Inflammation
    Suzanne Oparil; Fiscal Year: 2007
    ..These fundamental mechanistic studies will enhance our understanding of the pathobiology of vascular disease, particularly as it occurs in aging women, and will provide the basis for development of novel therapeutic strategies. ..
  11. ADVENTITIAL RESPONSE TO VASCULAR INJURY: ESTROGEN
    Suzanne Oparil; Fiscal Year: 2003
    ..These fundamental mechanistic studies will establish more rational strategies for therapeutic intervention in vascular diseases, including the basis for future gene therapy. ..
  12. Novel Risk Factors for Chronic Kidney Disease
    Ronald Klein; Fiscal Year: 2008
    ..The new data may provide insights into the relative protective value of low levels of these markers on the incidence CKD in an aging population. [unreadable] [unreadable] [unreadable]..
  13. Multi-Ethnic Study of Atherosclerosis-Eye Study
    Ronald Klein; Fiscal Year: 2005
    ..insights into the relative contribution of microvascular disease to the pathophysiology and natural history of subclinical and clinical cardiovascular disease, in representative populations of men and women of diverse ethnicities ..
  14. PAI-1 and The Vascular Toxicity of Aldosterone
    Nancy Brown; Fiscal Year: 2005
    ..This multi-disciplinary approach will generate new information regarding the role of aldosterone in vascular toxicity and, thus, improve our ability to prevent and treat cardiovascular disease. ..
  15. Identification of Serum Markers of Liver Fibrogenesis/ Fibrolysis by Proteomics
    Detlef Schuppan; Fiscal Year: 2008
    ..Adaptation to the human proteome and prospective validation shall allow noninvasive monitoring of fibrosis progression and regression in patients with liver diseases. [unreadable] [unreadable] [unreadable]..
  16. Microvascular - Macrovascular Disease in Type 2 Diabetes
    Ronald Klein; Fiscal Year: 2005
    ....
  17. Mouse Models for Celiac Disease
    Detlef Schuppan; Fiscal Year: 2007
    ..g. by immunomodulatory cytokines or by cytokine antagonists. It is anticipated that the results will improve our understanding and management of cd and related autoimmune diseases. ..
  18. RAAS, Inflammation & Post-Operative Atrial Fibrillation
    Nancy Brown; Fiscal Year: 2009
    ..abstract_text> ..
  19. African American Study of Kidney Disease and Hypertensi*
    Robert Toto; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
  20. Lipoproteins, HIV, and Antiretroviral Therapy in SMART
    Daniel Duprez; Fiscal Year: 2008
    ..This proposal will produce additional information that will enhance their disease-free survival rate. (End of Abstract) [unreadable] [unreadable] [unreadable]..
  21. Vanderbilt Mentored Clinical Research Scholar Program
    Nancy Brown; Fiscal Year: 2006
    ..The VCRS program will train successful new clinical investigators who will serve as leaders role in the post-genomic era. [unreadable] [unreadable] [unreadable]..
  22. Circumventricular Organs and Cardiovascular Regulation
    JOHN COLLISTER; Fiscal Year: 2007
    ..The results of these studies will greatly enhance our understanding of the central effects of Angll at two specific brain regions, and how these interactions play a role in the long-term control of arterial pressure. ..
  23. Diabetes and Drug-Associated Hyperkalemia: Effect of Laboratory Monitoring
    Marsha Raebel; Fiscal Year: 2008
    ..The findings will also assist in developing a framework for future studies to evaluate the effects and costs of medication-laboratory monitoring among patients with diabetes. [unreadable] [unreadable] [unreadable] [unreadable]..
  24. WISCONSIN EPIDEMIOLOGICAL STUDY OF CARDIOVASCULAR DISEAS
    Ronald Klein; Fiscal Year: 2002
    ....
  25. ANGII NEURAL INTERACTIONS IN CARDIOVASCULAR CONTROL
    JOHN COLLISTER; Fiscal Year: 2002
    ..Upon completion, Dr. Collister will have fully developed into an independent investigator. ..
  26. HIGH RESOLUTION ECHOCARDIOGRAPHY SYSTEM
    Michael Zile; Fiscal Year: 2001
    ..This will foster interdisciplinary investigation, support NIH-funded investigators and trainees, and enhance the competitiveness of MUSC investigators. ..
  27. RETINAL ARTERIOLAR ABNORMALITIES AND CV MORTALITY
    Ronald Klein; Fiscal Year: 2002
    ..Data from this study will improve the understanding of the association between microvascular characteristics and cardiovascular mortality. ..
  28. Retinal Microvascular Characteristics/Vascular Disorders
    Ronald Klein; Fiscal Year: 2003
    ..abstract_text> ..
  29. TRAINING CURRICULUM IN PATIENT ORIENTED RESEARCH
    Robert Toto; Fiscal Year: 2004
    ..The proposed program will provide young physicians and scientists with the skills needed to conduct clinical investigations and to compete for federal and non-federal research funding. ..
  30. Improving Outcomes in Diabetic Nephropathy
    Robert Toto; Fiscal Year: 2008
    ..the renin-angiotensin-aldosteronesystem withangiotensin convertingenzyme inhibitors(ACEIs) or angiotensin II type 1 receptor blockers(ARBs)...
  31. Genetics of Chronic Kidney Disease
    Stephen T Turner; Fiscal Year: 2010
    ..abstract_text> ..
  32. ANGIOTENSIN II AND BRADYKININ IN CARDIAC HYPERTROPHY
    LOUIS DELL ITALIA; Fiscal Year: 2007
    ..These studies will uncover new mechanistic insights and therapeutic strategies for VO. ..
  33. Atrial Fibrillation: Incidence, Risk Factors, and Genetics
    SUSAN HECKBERT; Fiscal Year: 2010
    ..The ultimate goal of this research is to increase knowledge about AF risk factors and prognosis and to enhance prevention efforts and improve care for patients with AF. ..
  34. Natriuretic mechanisms of AT2 receptors
    ROBERT MUNSON CAREY; Fiscal Year: 2010
    ..This application will increase our understanding of the mechanisms whereby the kidney renin-angiotensin system regulates salt and water excretion, suggesting new molecular targets for the treatment and prevention of hypertension. ..
  35. Renal medullary COX-2 in blood pressure control
    Tianxin Yang; Fiscal Year: 2008
    ..The information resulted from these studies will provide new insight into the molecular mechanism responsible for long-term control of arterial blood pressure. ..
  36. Impact of Medicaid Prescription Copayments in Patients with Schizophrenia
    Jalpa Doshi; Fiscal Year: 2009
    ..The findings of our study will help inform policymakers about the intended and unintended consequences of prescription copayments in Medicaid patients with schizophrenia. ..
  37. UW Multidisciplinary Clinical Research Training (RMI)
    Jeffrey Probstfield; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  38. PRESSURE NATRIURESIS MEDIATED BY EXTRACELLULAR cGMP
    Robert Carey; Fiscal Year: 2009
    ..Proof of the specific aims will identify and characterize a novel role of extracellular Rl cGMP and provide a potential therapeutic target for hypertension and other disease states associated with sodium retention. ..
  39. The Renin-Angiotensin System, Inflammation and Radiation-induced Brain Injury
    Michael E Robbins; Fiscal Year: 2010
    ....
  40. Salsalate: A Diabetes Treatment for Carbonyl, Oxidative & Nitrosative Stress
    JOSHUA ISRAEL BARZILAY; Fiscal Year: 2010
    ..If effective, this treatment could reduce the risk of heart attacks and strokes that frequently occur in people with diabetes. ..
  41. PATHOPHYSIOLOGY OF DIABETIC NEPHROPATHY
    Sharon Anderson; Fiscal Year: 2007
    ..abstract_text> ..
  42. Human monoclonal antibody therapy for HUS
    Howard Trachtman; Fiscal Year: 2004
    ..abstract_text> ..
  43. Folic Acid Intake and Risk of Hypertension
    John Forman; Fiscal Year: 2004
    ..Subsequently, the risk of hypertension will be analyzed in > 2000 men and women genotyped for eNOS, and > 7000 men and women genotyped for MTHFR. Interaction with folate will be analyzed. ..
  44. Dysregulation of AT, receptor in Transgenic Rats
    MICHELLE CLARK; Fiscal Year: 2004
    ..abstract_text> ..
  45. Renal Microcirculatory and Tubular Dynamics
    Joey Granger; Fiscal Year: 2004
    ....
  46. Circulatory Dysfunction in Chronic Fatigue Syndrome
    Julian Stewart; Fiscal Year: 2004
    ....
  47. Molecular Modulation of Cardiac Na+ Channel Function
    Katherine Murray; Fiscal Year: 2004
    ..abstract_text> ..
  48. Fatty Acids, Angiotensin and Oxidative Stress
    Brent Egan; Fiscal Year: 2004
    ..We believe the information generated by the proposed studies has the potential for elucidating biological mechanisms underlying obesity-associated hypertension and the potential for dietary anti-oxidants to modulate BP. ..
  49. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 2002
    ....
  50. Intercellular Signaling in Obstructive Nephropathy
    ROBERT CHEVALIER; Fiscal Year: 2005
    ..This will lead to improved outcomes in adulthood. ..
  51. Regulation of minerals and fluids excretion in vitamin D
    Yan Chun Li; Fiscal Year: 2005
    ..The third goal is to study the effect of VDR inactivation on ANP expression and sodium and body fluid balance, in order to test in vivo, the hypothesis that 1,25(OH)2D3 negatively regulates ANP expression. ..
  52. GENETIC EPIDEMIOLOGY OF RESPONSES TO ANTIHYPERTENSIVES
    Stephen Turner; Fiscal Year: 2006
    ....
  53. Mechanisms of Oxidant Signaling in Post-MI Remodeling
    Wilson Colucci; Fiscal Year: 2007
    ..These studies will provide new understanding of the mechanisms of oxidant signaling in myocardial remodeling post-MI, and will therefore have direct relevance to a common cause of heart failure in patients. [unreadable] [unreadable]..
  54. Cardiovascular Effects of lyengar Yoga
    Raymond Townsend; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  55. Interaction of COX-2 and nNOS in renin secretion
    Tianxin Yang; Fiscal Year: 2006
    ....
  56. Life Cycle Effects of Health Insurance on Elderly Health
    Jalpa Doshi; Fiscal Year: 2006
    ..We will use these estimates to simulate the effect of changes in the age of Medicare eligibility on health, medical service use and Medicare expenditure. ..
  57. Beta3-Adrenergic Receptor & Progression to Heart Failure
    Che Ping Cheng; Fiscal Year: 2006
    ..Thus, provide valuable new insight into the mechanism of the progression of functional impairment in CHF, and may assist in specifically targeting therapy for CHF. ..
  58. Renal & Cellular Studies in Type 1 Diabetic Patients
    S Mauer; Fiscal Year: 2007
    ..These studies will provide markers and predictors of DN risk, determine if these are genetically regulated or dependent on prior exposure to D, and identify DN pathogenetic pathways. ..
  59. POSTMENOPAUSAL HORMONAL REPLACEMENT THERAPY
    Wanpen Vongpatanasin; Fiscal Year: 2006
    ..The long-term goal of her work would be the discovery the most effective estrogen preparation that can prevent or treat hypertension in women after menopause. ..
  60. UW CLINICAL RESEARCH TRAINING PROGRAM
    Jeffrey Probstfield; Fiscal Year: 2004
    ..abstract_text> ..
  61. ROS and NO interaction in the PVN during hypertension?
    CARRIE NORTHCOTT; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  62. CELL GROWTH, NA/H EXCHANGE, AND CYCLINS IN IDDM PATIEN
    Daniel Batlle; Fiscal Year: 2002
    ....